Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC
NCT07873086Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2026
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
Open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Peking University People's Hospital. Primary endpoint: Disease-Free Survival at 2 years. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07873086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07873086.